Navigation Links
Fuisz Pharma Announces Intent to Divest Strategic Patent for Detection of Opioid Abuse; Seeks Offers for Patent through May 2013

MIAMI, April 22, 2013 /PRNewswire-USNewswire/ -- Fuisz Pharma today announced its intent to divest its strategic issued patent for the detection of opioid abuse (US 7,214,385 "Pharmaceutical Formulation Containing Dye").  This patent covers the use of dyes and staining agents in pharmaceutical dosage forms as a method to prevent the improper use of opioid drugs by visually demonstrating their misuse and abuse.  For example, where a patient abuses a drug like oxycodone through nasal snorting, this patented system leaves a stain in the nasal cavity that can be used by care givers, law enforcement, and family to determine that abuse is occurring. It does not leave a stain if taken properly by mouth.

Fuisz Pharma's Managing Member, Joseph Fuisz commented: "In the FDA's decision this month approving the withdrawal of the old Oxycontin® formulation for safety reasons thereby stopping generic companies from using that product as a reference drug, the FDA has given a strong economic incentive to innovators to deploy deterrent features to prevent abuse.  In reaching this conclusion, the FDA specifically cited intranasal abuse as well as evidence that the new Oxycontin® formulation reduced intranasal abuse."

Richard Fuisz , M.D., Founding Member, commented, "It is but a matter of time before there is an increasing recognition that abuse detection is an essential component of abuse deterrence. This is the bedrock patent of abuse recognition by the care giver, the emergency room personnel and law enforcement resulting in a powerful deterrent to abuse."

Mr. Joseph Fuisz continued: "The patented dye-stain system described in the '385 can be used independently as a feature, or stacked together with other deterrent features like crush resistance.  This ability to stack multiple features is particularly advantageous insofar is more deterrence is better.  Moreover, many formulation techniques for crush resistance do not enjoy patent protection.

"Divesting this asset will allow us to better focus on our other drug delivery assets, including the Saturn™ tablet designed for improved esophageal transit and increasingly a focal point of therapeutic and potential product liability concern with regard to unnecessary esophageal excoriation by a whole group of drugs that can cause damage when esophageal transit fails.

"We will accept offers for the '385 through the end of May 2013, but reserve the right to enter into a transaction earlier or otherwise refuse offers.  Interested parties should contact Fuisz Pharma."

Fuisz Pharma is a private pharmaceutical technology company originated by the Fuiszes. The Fuiszes have made substantial contributions in drug delivery including orally dissolving tablets and novel particle coating systems at Fuisz Technologies; inventing and developing thin film drug delivery technologies at Kosmos Pharma and MonoSol Rx, as well as independently developing extruded sheet technology, diagnostics and having extensive experience working with big and specialty pharma. Fuisz Pharma has its headquarters in Miami.

SOURCE Fuisz Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Fuisz llc Announces Induction of Richard C. Fuisz, M.D., into Georgetown Universitys 1789 Society.
2. Fuisz Pharma Announces Patent Allowance For New Tablet And Caplet Shapes That Promote Rapid, Reliable Esophageal Transit
3. Pharmagen to Present Strategic Vision for Solving Nations Parenteral Drug Shortage Crisis at 2013 BIO International Convention
4. New PAREXEL Report Defines The Next Generation Of Strategic Partnerships Between CROs And Biopharmaceutical Industry
5. Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc.
6. Statement from the Cystic Fibrosis Foundation on Promising Phase 2 Clinical Trial Results of Kalydeco and VX-661 (Vertex Pharmaceuticals Inc.)
7. The Politics of Pharma: Washington, States, and the Courts Impact on the Industry
8. Biopharmaceutical Managed Care Strength Closely Intertwined with Marketplace Success
9. ADial Pharmaceuticals Announces Agreement With FDA For Phase III Trial Of AD04 For Alcohol Use Disorder In Patients Of Targeted Genotypes
10. Comparison of Biopharmaceutical Industry Between China and India 2013
11. Inovio Pharmaceuticals Universal H1N1 Influenza Vaccine Achieves Protective Immune Responses Comparable to Conventional Vaccine in Phase I Study
Post Your Comments:
(Date:12/1/2015)... Dec. 1, 2015 As enforcement of the ... Security Act (DSCSA) approaches, InfiniTrak announced ... pharmacies comply with looming FDA regulations. ... entering endorsement agreements with State Pharmacy Associations, an ... organization (PSAO) to exclusively provide the InfiniTrak track-and-trace ...
(Date:12/1/2015)... CLEVELAND , Dec. 1, 2015   ... innovation firm, today announced the publication of a ... Entering the Direct-to-Consumer Medical Market". The whitepaper gives ... roadmap for successfully penetrating this lucrative segment. ... purchase healthcare products to manage their own health, ...
(Date:12/1/2015)... 2015 --> --> ... Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, Vaccines, ... Pipeline Analysis - Global Forecast to 2020", published by MarketsandMarkets, ... 73,529.2 Million by 2020 from USD 40,281.6 Million in 2015, ... Browse 37 market data T ...
Breaking Medicine Technology:
(Date:12/1/2015)... Fla. (PRWEB) , ... December 01, 2015 , ... ... number of leadless pacemakers in the U.S. and is the only hospital in ... from the largest clinical data presentation of transcatheter pacing patients were revealed recently ...
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments per workers’ ... in utilization of hospital and nonhospital care, according to a recent study by the ... Louisiana, 16th Edition , found medical payments per claim with more than seven days ...
(Date:12/1/2015)... ... December 01, 2015 , ... It’s official: Tattoo taboo is ... a number even greater among Millennials (a whopping one in three aged 18 to ... people who are dissatisfied with their ink. In fact, RealSelf , the world’s ...
(Date:12/1/2015)... ... December 01, 2015 , ... For many X-rays taken at ... accurate interpretation by the radiologist. The marking utensils are so small, however, they ... found a way to alleviate this problem. , He developed the patent-pending MARK ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... it has been selected as a finalist in this year’s Fierce Innovation Awards: ... Next IT Healthcare was recognized as a finalist in the category of Digital ...
Breaking Medicine News(10 mins):